Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players

News provided by

Oct 01, 2024, 08:01 ET

Initiative aims to increase awareness of the relationship between chronic heartburn and esophageal cancer, and role of EsoGuard esophageal precancer testing

NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it held its inaugural educational session and #CheckYourFoodTube Precancer Testing Event targeting former NFL players in Cincinnati, Ohio.

This initiative aims to increase awareness of the relationship between gastroesophageal reflux disease (GERD), also known as chronic heartburn, and highly lethal esophageal cancer, as well as the opportunity to prevent this cancer through esophageal precancer detection using Lucid's EsoGuard^® Esophageal DNA Test. The event, hosted by Brian J. deGuzman, M.D., Lucid's Chief Technology and Compliance Officer, featured a comprehensive educational session followed by on-site testing of Cincinnati-based former NFL players who are at risk of having esophageal precancer. Lucid plans to expand these educational and testing events targeting former NFL players to other cities across the nation.

"Collaborating with Lucid Diagnostics on this inaugural event is just the beginning of what we hope will be a game-changing initiative for former NFL players across the country," said Solomon Wilcots, former NFL player for the Cincinnati Bengals and Team Leader of Sports-Health Alliance at Russo Partners. "As athletes who've put our bodies on the line throughout our careers, we have a heightened awareness of the importance of protecting our long-term health. EsoGuard offers us a crucial opportunity for early detection of esophageal precancer, which can truly be a lifesaver. I strongly encourage all my peers in the sports community to take proactive steps in safeguarding their health from this deadly, yet preventable cancer. Remember, when it comes to esophageal cancer, early detection is the best—it's time we all 'Check Our Food Tubes!'."

"These educational and precancer testing events targeting former NFL players provide us with a great opportunity to increase awareness of highly lethal but now preventable esophageal cancer," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "Individuals with heartburn and other risk factors (age over 50, male, white race, obesity, smoking or a family history), whether former NFL players or their legions of fans, can now undergo a quick and simple test to determine whether they may have precancer and take appropriate steps to prevent this cancer. We are committed to getting the word out and appreciate Mr. Wilcots and his compatriots using their platform to help us do so."

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

SOURCE Lucid Diagnostics